Immunotherapy and immunoprevention of cancer: where do we stand? - Wikidata - awgldk - TriplyDB

Immunotherapy and immunoprevention of cancer: where do we stand?

Immunotherapy and immunoprevention of cancer: where do we stand?

http://www.wikidata.org/entity/Q36150524

about

Dendritic cell-based cancer immunotherapy for colorectal cancer CCR3, CCR4, CCR5, and CXCR3 expression in peripheral blood CD4+ lymphocytes in gastric cancer patients.

P2860

Q26751339-A4636C72-F63F-4DAB-914E-5490487235DA Q42147878-1FD2A91B-FBF9-474E-B7C8-62B37C4E96C2

P2860

Immunotherapy and immunoprevention of cancer: where do we stand?

http://www.wikidata.org/entity/Q36150524

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Immunotherapy and immunoprevention of cancer: where do we stand?

@ast

Immunotherapy and immunoprevention of cancer: where do we stand?

@en

type

label

Immunotherapy and immunoprevention of cancer: where do we stand?

@ast

Immunotherapy and immunoprevention of cancer: where do we stand?

@en

prefLabel

Immunotherapy and immunoprevention of cancer: where do we stand?

@ast

Immunotherapy and immunoprevention of cancer: where do we stand?

@en

P1433

Q36150524-577E1A6F-AAF6-4956-8B8A-F8A3EFEF9C99

P1476

Q36150524-4820EEAF-F1EF-4A1D-A8AE-7EE17AF48751

P2093

Q36150524-05179124-AA6D-485A-9C0F-0B98BD552386

Q36150524-60B652EB-DD4F-4592-8542-F9C064A52608

Q36150524-6E6E01F1-D3FB-48A8-83DA-FD7FA2CBD54E

P2860

Q36150524-04A0D1B8-E183-4869-9DD9-99B54EC330E2

Q36150524-07A50493-A72F-425A-8418-4499347FBCE5

Q36150524-0AE37A9B-CE74-4AAE-9D24-2C4C5F371C30

Q36150524-0E3B4E9F-A5A8-4AAE-B9E8-570501F4BC0F

Q36150524-1098BBBE-9A93-4AD3-AEF7-4BA4E71FBFD5

Q36150524-181FB90E-B651-4846-978B-DAC28CFD17CB

Q36150524-29BE28A6-5732-422D-BEAA-E8816C98AAFC

Q36150524-2E66B35F-33BC-4853-8514-A70C25A2D0B8

Q36150524-33A4E86D-7F52-4169-90B6-D9364513FC8A

Q36150524-3D72DD30-5D4C-450F-BB55-373B201BF2D0

P304

Q36150524-55CAC4EE-568B-4B97-84D1-8151D9D8E489

P31

Q36150524-DBCA6EFA-6C9C-4920-A41F-ADBE8260CCE6

P356

Q36150524-B0A550CD-28A4-42E0-A855-DBE3772D0C75

P407

Q36150524-D3638A8D-718A-43EB-B9E7-B243766D8000

P433

Q36150524-C748C07A-1F1D-43F8-95A4-F1026EB665D9

P478

Q36150524-241F7873-F82C-4E6C-BFA3-2BB65C76D2E8

P577

Q36150524-68630CA6-92A0-46F6-A82A-E8C0F6E204A6

P698

Q36150524-51F91E0D-C0F2-4571-BD0C-083A348FED94

P356

14712598.5.5.717

P1433

Expert Opinion on Biological Therapy

P1476

Immunotherapy and immunoprevention of cancer: where do we stand?

@en

P2093

Claudia Curcio

http://www.w3.org/2001/XMLSchema#string

Federica Cavallo

http://www.w3.org/2001/XMLSchema#string

Guido Forni

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

TLR signaling pathways

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Forecasting the cytokine storm following systemic interleukin (IL)-2 administration

Continuous cultures of fused cells secreting antibody of predefined specificity

The immunobiology of cancer immunosurveillance and immunoediting

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

Antibodies and genetically engineered related molecules: production and purification.

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

P304

717-726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.5.5.717

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15934846

http://www.w3.org/2001/XMLSchema#string